Autoimmune Disease Diagnostics Market: as rising global autoimmune disease prevalence pushes multiplex autoantibody panel adoption onto closed cobas, Atellica, and Alinity i systems, laboratory consolidation converts single-plex immunofluorescence volumes into higher-reagent-revenue automated workflows, so per-patient test revenue compounds above underlying patient volume growth, and IVDR compliance in Europe is concentrating new platform wins around the first movers who clear the regulatory threshold.

The global autoimmune disease diagnostics market size was USD 6.18 Billion in 2025 and is expected to register a revenue CAGR of 6.4% during the forecast period. Market revenue growth is driven by factors such as rising global autoimmune disease prevalence and expanding patient diagnostic needs, laboratory consolidation onto closed-system high-throughput immunoassay platforms, and CMS and payer reimbursement frameworks supporting autoantibody panel testing volume. The first driving factor is the rising global burden of autoimmune disease. More than 50 million Americans live with an autoimmune condition per the American Autoimmune Related Diseases Association, and the NIH identifies autoimmune diseases as affecting 5 to 8 percent of the US population, generating sustained high-volume autoantibody test demand at hospital clinical laboratories and specialist reference laboratory settings. The second driving factor is laboratory consolidation onto closed-system immunoassay analyzer platforms. As hospital and regional laboratory networks upgrade from legacy single-plex indirect immunofluorescence ANA testing to automated cobas, Atellica, and Alinity i platforms, every ANA-positive screen automatically triggers confirmatory specific autoantibody reflexing on the same closed-system platform, increasing reagent revenue per patient above the underlying patient volume growth rate. The third driving factor is stable CMS reimbursement for autoimmune biomarker panels. CMS procedural reimbursement for ANA, anti-dsDNA, anti-CCP, rheumatoid factor, and complement component assays provides predictable recurring revenue that supports laboratory capital investment in high-throughput autoimmune marker processing platforms. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way each closed-system immunoassay platform placement generates a long-term reagent annuity, which compounds in value as the laboratory's autoimmune test menu expands onto the same installed instrument over time. Once a hospital laboratory upgrades to the cobas or Atellica platform, each additional autoimmune assay added to the menu requires no new analyzer capital spend and no new procurement process, so the reagent revenue per installed platform compounds as the menu broadens around it. As a result, demand and revenue share are concentrating around closed-system platform vendors that hold the broadest autoimmune assay menus with IVDR or FDA regulatory clearance, and the forecast tilts toward these reagent-annuity incumbents rather than open-system single-analyte test kit suppliers. For instance, in April 2025, Thermo Fisher Scientific launched a fully automated ANA screening platform with AI-powered interpretation capable of processing high-throughput tests at hospital and large reference laboratory settings, adding one of more than a dozen AI-enabled autoimmune diagnostic investments the major platform vendors have made in the 2025 to 2026 period and confirming that the competitive advantage of the reagent annuity model is now being extended to AI-enhanced interpretation layers that further lock menu decisions to the platform vendor. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the structural transition from legacy single-plex indirect immunofluorescence ANA testing to closed-system automated immunoassay platforms at hospital and regional reference clinical laboratories. Automated immunoassay platforms work for autoimmune diagnostics only when the laboratory's full autoantibody menu is carried on the same closed instrument, and accreditation standards increasingly require confirmatory specific autoantibody follow-up to every ANA-positive screen, so ANA screen and specific panel arrive together on the same platform reagent contract. The recent record shows the pace. Roche Diagnostics reported 9% growth in immunodiagnostic products in fiscal 2024 per the company's Annual Report, with the Elecsys autoimmune immunoassay menu on cobas e 601 and cobas e 801 platforms providing automated anti-dsDNA, anti-Sm, anti-Ro/SSA, anti-La/SSB, anti-Jo-1, and ANA screen assays at hospital clinical laboratories, and Siemens Healthineers signed a multi-year agreement valued at more than EUR 200 million with Unilabs in February 2023 for deployment of over 400 laboratory analyzers including Atellica Solution immunoassay platforms. The effect on the market is a structural per-patient revenue uplift at every laboratory that converts from manual IIF to automated closed-system immunoassay, creating a growth rate that persists above underlying patient volume growth as long as laboratory consolidation continues. These are some of the key factors driving revenue growth of the market.

The second driver is the sustained rise in diagnosed autoimmune disease patient populations requiring serial autoantibody monitoring throughout their treatment course. Rising prevalence works as a volume driver because autoimmune disease management requires serial testing rather than a one-time diagnosis, and each patient on immunosuppressive therapy for rheumatoid arthritis, SLE, or multiple sclerosis generates repeat anti-CCP, anti-dsDNA, and complement panel test orders at six to twelve month intervals, so the patient stock compounds into a high-frequency recurring test volume base. More than 50 million Americans live with an autoimmune disease per the American Autoimmune Related Diseases Association, and the WHO Global Burden of Disease study documents approximately 18 million people globally with rheumatoid arthritis, with anti-CCP antibody and rheumatoid factor serology representing among the highest-volume specific autoantibody test categories at hospital and reference clinical laboratories. In February 2025, Siemens Healthineers announced the expansion of its autoimmune testing panel on the Atellica IM platform with new connective tissue disease marker assays per the company's product announcement, and in January 2025, Roche Diagnostics CEO Matt Sause identified autoimmune disease prevalence and growing awareness as contributing factors to the immunodiagnostics growth documented in the company's fiscal 2024 earnings. The effect on the market is a growing, predictable recurring test volume base at hospital and reference laboratories that justifies continued capital investment in high-throughput closed-system autoimmune marker processing platforms by the dominant reagent annuity vendors. These are some of the key factors driving revenue growth of the market.

"More than 50 million Americans live with an autoimmune disease, and each patient on serial immunosuppressive therapy generates repeat anti-CCP, anti-dsDNA, and complement panel test orders at six to twelve month intervals. That recurring test cadence is why the autoimmune diagnostics market compounds above a single-episode testing category and why closed-system platform incumbents with the broadest autoimmune assay menus hold the most durable revenue positions."

Clarivant Market Sizing Model, 2025

The third driver is the regulatory compliance barrier created by the European Union's In Vitro Diagnostic Regulation for multiplex autoimmune assay platforms serving European clinical laboratories. IVDR compliance is a necessary condition for platform placement at European accreditation-required laboratories, and achieving IVDR CE Mark for a multiplex autoimmune panel requires significant clinical evidence generation and notified body assessment time, so compliance creates a regulatory moat that separates cleared first movers from competitors still navigating their own IVDR submission processes. In February 2025, AliveDx obtained IVDR-CE Mark for the MosaiQ AiPlex CTDplus multiplex assay per company announcement, becoming the first multiplex systemic autoimmune rheumatic disease diagnostic assay to achieve full IVDR compliance for European clinical laboratory deployment, with European accreditation bodies including COFRAC in France, DAkkS in Germany, and UKAS in the UK progressively requiring IVDR-compliant IVD assays as part of accreditation standard updates. The effect on the market is a commercial window of approximately 18 to 24 months for IVDR-cleared multiplex autoimmune platforms to build accreditation-driven laboratory placements before major platform vendors complete their own IVDR submission processes, creating a first-mover advantage dynamic that will shape the European multiplex autoimmune panel competitive structure through 2026 and into the early forecast years. These are some of the key factors driving revenue growth of the market.

However, the autoimmune disease diagnostics market faces adoption constraints from the high ANA false-positive rate in healthy individuals and the cost and reimbursement barriers that limit multiplex panel penetration in price-sensitive markets. The ANA false-positive rate in healthy individuals is estimated at approximately 15% per published clinical literature and acknowledged in the 2024 ACR/EULAR updated classification criteria for systemic autoimmune rheumatic diseases, which generates unnecessary follow-up specific autoantibody confirmatory testing at laboratories that do not apply structured ANA reflex testing protocols, so the effective test yield per ANA-positive patient is diluted and the clinical credibility of high-volume ANA screening programmes is challenged in settings that lack protocol-driven reflex cascade workflows. High multiplex panel cost compounds this, because BioPlex 2200 and Luminex-based multiplex autoimmune panels range from USD 150 to USD 300 per panel, and healthcare system per-capita spending in lower-income emerging markets averages USD 50, which forces reliance on single-analyte immunoassays that are less clinically informative, and China's 2024 volume-based procurement programme, which reduced immunoassay reimbursement rates for the dominant cobas platform, illustrates the pricing reform risk that compresses revenue growth below volume growth in the largest emerging market for autoimmune diagnostics. Diagnostic delay is a third constraint, since the average time from initial autoimmune symptom presentation to confirmed diagnostic testing referral is four to six years across the systemic autoimmune disease spectrum per published rheumatology literature, so the addressable diagnosed patient pool receiving repeat serial autoantibody monitoring is substantially smaller than the true underlying autoimmune disease prevalence, and platforms without primary care ordering pathways for autoimmune screening struggle to accelerate the conversion of undiagnosed prevalence into test volume. These factors substantially limit autoimmune disease diagnostics market growth over the forecast period.

Based on technology, the global autoimmune disease diagnostics market is segmented into automated immunoassay, indirect immunofluorescence, multiplex bead array, and molecular and genetic testing. Automated immunoassay holds the largest revenue share, because the closed-system cobas, Atellica, ARCHITECT, and Alinity i immunoassay platforms at hospital clinical laboratories process the majority of autoimmune marker test volume globally and generate recurring reagent annuity revenue that compounds as the autoimmune assay menu broadens on each installed instrument, which suits the laboratory consolidation trend driving high-throughput immunoassay platform adoption. Indirect immunofluorescence and multiplex bead array platforms remain established for HEp-2 ANA screening and comprehensive specific autoantibody profiling respectively, and they are more cost-accessible for individual specialist tests, but they cannot match the throughput, automation, and menu breadth of the closed-system automated immunoassay platforms at high-volume hospital laboratory settings. Multiplex bead array, encompassing Bio-Rad BioPlex 2200 and Luminex xMAP-based autoimmune panels, is expected to register a rapid revenue growth rate in the global autoimmune disease diagnostics market over the forecast period, driven by clinical laboratory accreditation programme shifts toward multiplex-confirmed specific autoantibody results and AliveDx's IVDR-CE Mark first-mover advantage in IVDR-compliant multiplex autoimmune panel deployment at European accreditation-required laboratories.

Based on disease, the global autoimmune disease diagnostics market is segmented into systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes and islet autoimmunity, inflammatory bowel disease, multiple sclerosis and neurological autoimmune, and other systemic and organ-specific autoimmune diseases. Systemic autoimmune diseases collectively hold the largest disease segment revenue share at approximately 48% of 2025 market revenue, because SLE multi-organ manifestations require anti-dsDNA, complement C3/C4, anti-Sm, anti-Ro, and anti-La serial monitoring and rheumatoid arthritis requires anti-CCP, rheumatoid factor, and inflammatory marker serial monitoring throughout the treatment course, which generates the highest repeat test ordering frequency of any autoimmune disease category. Multiple sclerosis and neurological autoimmune is expected to register a rapid revenue growth rate in the global autoimmune disease diagnostics market over the forecast period, driven by blood-based neurofilament light chain monitoring as an alternative to serial MRI and Roche's receipt in April 2025 of FDA breakthrough device designation for the Elecsys Neurofilament Light Chain test for multiple sclerosis monitoring, confirming the expanding investment in the neurological autoimmune disease diagnostic category.

Based on end-use, the global autoimmune disease diagnostics market is segmented into hospital clinical laboratories, reference diagnostic laboratories, and specialist rheumatology and immunology clinics. Hospital clinical laboratories hold the largest revenue share through the closed-system immunoassay platform installed bases that process the majority of autoimmune marker test volume globally, because large hospital network laboratory consolidation contracts guarantee multi-year reagent volumes that justify the instrument capital investment and the accreditation-required protocol development for autoimmune assay menus. Reference diagnostic laboratories, including Quest Diagnostics and Labcorp in the United States and equivalent national reference laboratory networks in European countries, is expected to register the fastest revenue growth rate in the global autoimmune disease diagnostics market over the forecast period, driven by specialist autoimmune panel referral volumes from primary care and rheumatology outpatient settings and by the concentration of IVDR-compliant multiplex autoimmune panel capacity at reference laboratory accreditation-driven testing programmes in France, Germany, and the United Kingdom.

Based on regional analysis, the autoimmune disease diagnostics market in North America accounted for the largest revenue share in 2025. The United States leads because CMS reimbursement for autoimmune biomarker panels including ANA, anti-dsDNA, anti-CCP, and complement component assays provides stable procedural revenue that supports hospital laboratory capital investment in high-throughput closed-system immunoassay platforms, and because Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Beckman Coulter, and Thermo Fisher Scientific all have their primary commercial laboratory platform operations headquartered or substantially concentrated in the United States. Roche Diagnostics reported Core Lab revenue growth of 10% in the United States in fiscal 2024 driven by immunodiagnostic product demand, with the cobas immunoassay platform holding a verified leading position at US hospital laboratory networks, confirming the depth of the closed-system installed base advantage in the North American market. The concentration of FDA-cleared autoimmune diagnostic platforms and ACR/EULAR clinical guideline development in the United States also means that new autoimmune test approvals and updated classification criteria for SLE, RA, and other systemic autoimmune diseases are typically implemented in the United States first, before adoption cascades into European and Asia Pacific laboratory markets.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national autoimmune disease diagnostics markets within Europe, with Siemens Healthineers' EUR 200 million multi-year agreement with Unilabs covering over 400 European laboratory analyzer deployments providing verified evidence of the commercial scale of European laboratory immunoassay consolidation. In February 2025, AliveDx obtained IVDR-CE Mark for the MosaiQ AiPlex CTDplus multiplex assay, becoming the first multiplex systemic autoimmune rheumatic disease diagnostic platform to achieve IVDR compliance, creating a first-mover window before major platform vendors complete their own IVDR submissions. The European IVDR regulatory framework requires full IVDR compliance for new IVD placements and governs the pace of multiplex autoimmune panel adoption at accreditation-required clinical laboratories, doing well at ensuring clinical evidence standards for autoimmune diagnostic assays but creating friction in the form of extended notified body assessment timelines that delay new entrants, and the ongoing Iran-US sanctions and associated disruption to specialty biochemical reagent supply chains transiting Strait of Hormuz logistics corridors through 2026 has added import cost pressure on European autoimmune diagnostics manufacturers sourcing rare biochemical inputs. The result is steady rather than rapid growth, shaped more by regulatory compliance capacity and reagent supply resilience than by underlying patient demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and South Korea represent the three largest national autoimmune disease diagnostics markets within the region, with China accounting for the majority of Asia Pacific volume through its hospital clinical laboratory network that runs cobas and Atellica immunoassay platforms at major urban hospital centres. Roche's January 2025 earnings call specifically noted that China's volume-based procurement programme and reductions in immunoassay reimbursement rates had a meaningful impact on the diagnostics business in 2024, illustrating the pricing reform headwind that compresses revenue growth below underlying volume growth at the largest single autoimmune diagnostics market in Asia Pacific. bioMerieux reported Asia-Pacific region diagnostics growth of 11% in Q4 2024 with broad reagent volume strength across China and ASEAN markets per its FY2024 earnings release, confirming the underlying demand growth trajectory, and the nascent multiplex autoimmune testing adoption in Japan, South Korea, and Australia leaves more room for growth than in North America or Western Europe.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national autoimmune disease diagnostics markets within the region, with Brazil's private hospital laboratory networks including Fleury Medicina e Saude and Diagnosticos da America operating high-volume clinical chemistry and immunoassay platforms from Roche, Siemens Healthineers, and Abbott that include comprehensive autoimmune test menus for rheumatology and internal medicine physician ordering. Access to specialist multiplex autoimmune panel testing concentrates at private reference laboratories in Sao Paulo, Mexico City, and Bogota, while public health system laboratories in secondary cities rely on single-analyte ANA and rheumatoid factor testing. The Iran-US sanctions and Strait of Hormuz freight disruption have maintained elevated import costs for European-manufactured autoimmune immunoassay reagents and cold-chain diagnostics components shipped to Brazilian and Mexican private laboratory networks through 2026, slowing adoption of multiplex and IVDR-compliant autoimmune panel platforms beyond the primary urban commercial laboratory centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the United Arab Emirates represent the primary commercial autoimmune disease diagnostics markets within the GCC, driven by private hospital investment in Roche and Siemens Healthineers immunoassay platform infrastructure and growing rheumatology specialist physician capacity at major urban tertiary hospitals. South Africa is the most established market on the African continent for autoimmune diagnostics, with Netcare and Discovery Health private hospital laboratory networks running closed-system immunoassay platforms for ANA and specific autoantibody panel testing, while the Gulf Cooperation Council states are still building the specialist rheumatology outpatient infrastructure and autoimmune disease awareness that would drive test ordering volumes toward the reference laboratory capacity that the GCC's imported Roche and Siemens platforms already provide.